US Bitcoin company purchases Bitmain miners with bitcoin as collateral, achieving an effective discount of 44%
According to ChainCatcher, citing market sources, the latest quarterly report from the US Bitcoin company (NASDAQ: ABTC) disclosed that this year the company purchased approximately 11,298 S21 XP ASIC miners from Bitmain for a total of $49,400,000 (with a combined hash rate of about 3.05 EH/s), of which 80% of the payment was completed by pledging 314 BTC.
Based on this, the estimated protocol valuation for the pledged Bitcoin is approximately $125,900 per coin, while the average market price of BTC at the time was less than $70,000, reflecting a discount of about 44%. According to the agreement, Bitmain cannot forcibly liquidate the pledged BTC during the roughly 24-month redemption period. If, at maturity, the BTC price is higher than the protocol valuation, ABTC can choose to repay in cash and reclaim the BTC, locking in the appreciation; if the price is lower than the protocol valuation, they can forgo redemption and leave the BTC to Bitmain. This structure essentially grants ABTC a long-term call option on Bitcoin.
As of March 31, 2026, ABTC had pledged a total of 3,090 BTC to Bitmain, with a fair value of approximately $210,800,000, corresponding to miner purchase liabilities of about $364,300,000.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
Bernstein Downgrades Nvidia Rating and Target Price

Google (GOOGL.US) DeepMind launches AlphaGenome 2: Capable of decoding DNA cells with nearly double the mutation identification capacity
Google DeepMind has released its AI model AlphaGenome 2, which is trained on maps of over 100 millions of cells and has nearly double the ability of its predecessor in identifying gene expression variations.

